activity update, hmmmmm Looking at the upcoming milestones, I'll comment at the end; vs SP & volume...interesting study.
Most obviou is the lack of volumes, both on Nas & TSX , more or less zero trading.
One camp could easily argue all negative bias & say zero interst etc.
Alternativly one could argue the many thousands of sharholders, are not interested in selling.
institutions?
The number is not large, but did increase over past 6 months.certainly not last few weeks.
neither buying or selling.
insiders. Exact same story. Management still have sold zero shares.
Not buying either.
Essentially a wait & see situation on all sides of argument.
So as I started, I'll address what is on the docket to be waiting for.
First , kill the silly argument about 20+ years & all the noise about watste of time etc.
ONC , aka Pelareorep has been though mutiple sucsess & failure trials.
All of which yeild valuable information.
in the present day & time line up,,, which is what matters.
all expected within this quarter...aka before end of June.
1. FDA meeting update & details of MBc phase 3 trial. Much of the bracelet & aware-1, findings have been brought forward & requested to be included as part of the trial. Including the option of moving directly to registration.
2. The Pancreatic cancer phase 3 trial, details. Highly recommend & supported by CGAR. Notably as well fast track designation. Trial will be allowed to use in- place comparables. Resulting in half of the patients required & obviously faster & less expensive trial costs.
How many appreciate this cohurt #1, is co- therapy with Roche , tecentriq?
3. An additional cohurt of Gobblet has been initiated, from a $5 million grant. That was a competitive process & oncolytics biotech won. Based on the results of most recent gobblet trials.
4. Announcement of a very small trial, for anal cancer. Again part of the Gobblet trials.prelimanary results indicated 3x, improvement over alternative. Essentially there is no historical standard of care for anal cancer. They have indicated, that could leap- frog ahead of MBc & pancreatic cancer. Becoming a third opportunity for product registration.That patient enrolment is suggested to be announced this quarter.
5. Very technical & perhaps not significant, this Saturday presentation at ASCO with two abstracts.
no doubt will be a N.R. Next Monday with further details. Granted little significance.
So, knowing all that, certainly worth watching & waiting.
That mantra applies not only to existing sharholders., but also any potential partners or buyout offers.
historically Onc was looking to Pela as a lysis treatment. Recent studies have proven the biomarkers & the strong co- therapy opportunities.
Yes , I have covered most of this before. And yes all is available to read on Onc web site & recent publications.
Far better read than the childish, name calling & sarcastic nonsensical comments.
No volume. I agree 100%
Many are doing the wait & see thing.
Both on the buy & sell side.
The SP does not match the explained upside. That is mostly due to the long history.
Will Q2 reveal some, any or all of the above details?
consideing the mentioned 20+ years. The end game has now boiled down to the next 5 weeks.
Any of the 4 itemized opportunities, coming to fruition will be good news.
All 4 would be great news.
Zero of 4 terrible news.
irronically zero of the #1-#4 items are within Onc mangement control.
They are certainly involved. As also is Roche, the FDA & CGAR.
A negotiation concept well beyond many to grasp.
regards,
Live safe & healthy.